In conjunction with the reduced expression of DYRK2 in tumor samples, DYRK2 depletion promotes the proliferation of cell lines originating from distinct tumor types, including breast, lymphoma, osteosarcoma, CRC and HCC [56,136,137,138,139,145,158], suggesting that DYRK2 may acts as a brake on proliferation. Here, DYRK2 is linked to osteosarcoma.